Business Context and Reporting Period
Company: Techne Corporation (BIO-TECHNE Corp)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended December 31, 1995
Business Overview: The Company operates through two primary subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) in Minneapolis, and R&D Systems Europe Ltd. in Abingdon, England. Operations are divided into Biotechnology (cytokines, antibodies, assay kits) and Hematology (blood controls and calibrators) divisions. In fiscal 1996, R&D Europe opened a sales subsidiary in Germany.
Key Financial Metrics
| Metric | Quarter Ended 12/31/95 | Six Months Ended 12/31/95 |
|---|---|---|
| Sales | $12,514,479 | $25,308,777 |
| Gross Margin | $7,881,517 (63.0%) | $16,011,918 (63.3%) |
| Net Earnings | $1,687,753 | $3,473,035 |
| Earnings Per Share (Diluted) | $0.17 | $0.36 |
| Cash & Cash Equivalents | $4,102,802 | $4,102,802 (Ending Balance) |
| Short-Term Investments | $11,155,052 | $11,155,052 (Ending Balance) |
| Total Current Assets | $27,434,663 | $27,434,663 (Ending Balance) |
| Total Current Liabilities | $3,826,491 | $3,826,491 (Ending Balance) |
| Long-Term Debt | $0 | $0 |
| Operating Cash Flow (6 Months) | N/A | $3,923,489 |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 10% for the quarter and 13% for the six-month period compared to the prior year. Growth was driven by a 16% increase in R&D Europe sales and a 7% increase in R&D Systems sales.
- Margin Expansion: Gross margins improved to 63.0% (quarter) and 63.3% (six months) from 60.9% and 60.1% in the prior year, respectively. This was attributed to favorable product mix changes in R&D Europe and the Hematology Division.
- Expense Increases:
- Selling, General, and Administrative (SG&A) expenses rose 9% (quarter) and 17% (six months), largely due to the opening of a German subsidiary and increased sales staff.
- Research and Development (R&D) expenses increased 18% (quarter) and 22% (six months) to support new product lines, including murine assay kits and molecular biology products.
- Capital Expenditures: Capital additions surged to $4.18 million for the six months ended December 31, 1995, compared to $0.52 million in the prior year. This included a $3.22 million partial payment for leasehold improvements at the 2201 Kennedy building.
- Stock Repurchases: The Company repurchased 32,500 shares for $607,753 during the six-month period as part of a $5 million authorization plan.
Guidance, Outlook, and Risks
- Outlook: Management expects revenues to accelerate to record levels in the second half of fiscal 1996, driven by new product releases (murine assay kits, molecular biology products) and post-holiday season increases.
- Liquidity: The Company holds approximately $15.26 million in cash and short-term investments. It maintains an unsecured line of credit of $750,000. Management believes current funds and operating cash flow are sufficient to meet future requirements.
- Capital Needs: Approximately $2.2 million in capital expenditures are planned for the remainder of fiscal 1996, to be financed through operating cash and investment maturities.
- Risks: Key risks include the acceptance of new products, price competition in the cytokine market, retention of hematology OEM business, and the success of European marketing expansion.
- Dividends: The Company has never paid dividends and has no plans to do so in fiscal 1996.
Investor Verification Checklist
- Capital Expenditure Utilization: Verify the occupancy timeline and revenue impact of the new 2201 Kennedy building leasehold improvements ($3.22M invested).
- European Expansion Costs: Monitor the profitability timeline for the new German subsidiary and associated SG&A increases.
- Product Mix Sustainability: Assess whether the improved gross margins (driven by higher-margin in-house products) are sustainable or temporary.
- Stock Repurchase Progress: Track the remaining balance of the $5 million share repurchase authorization ($3.7M remaining as of Feb 1, 1996).
- Debt Status: Confirm the Company remains debt-free regarding long-term obligations, relying solely on cash reserves and a $750k line of credit.